Evaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)

References

• Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–14. doi: 10.1056/NEJM198809013190901
   PubMed Web of Science ®Google Scholar
• Muller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016;469(2):125–134. doi: 10.1007/s00428-016-1956-3
   PubMed Web of Science ®Google Scholar
• Harada S, Morlote D. Molecular pathology of colorectal cancer. Adv Anat Pathol. 2020;27(1):20–26. doi: 10.1097/PAP.0000000000000247
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–2054. doi: 10.1056/NEJMra023075
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–692. doi: 10.1016/j.cell.2007.01.029
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148–1159. doi: 10.1056/NEJMra072067
   PubMed Web of Science ®Google Scholar
• Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology. 2012;143(6):1442–1460 e1441. doi: 10.1053/j.gastro.2012.09.032
   PubMed Web of Science ®Google Scholar
• Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998;95(12):6870–6875. doi: 10.1073/pnas.95.12.6870
   PubMed Web of Science ®Google Scholar
• Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA. 1998;95(15):8698–8702. doi: 10.1073/pnas.95.15.8698
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96(15):8681–8686. doi: 10.1073/pnas.96.15.8681
   PubMed Web of Science ®Google Scholar
• Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2020;17(1):11–32. doi: 10.1038/s41571-019-0241-1
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology. 2015;149(5):1204–1225 e1212. doi: 10.1053/j.gastro.2015.07.011
   PubMed Web of Science ®Google Scholar
• Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA. 2000;97(2):710–715. doi: 10.1073/pnas.97.2.710
   PubMed Web of Science ®Google Scholar
• van Rijnsoever M, Grieu F, Elsaleh H, et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 2002;51(6):797–802. doi: 10.1136/gut.51.6.797
   PubMed Web of Science ®Google Scholar
• Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122(5):1376–1387. doi: 10.1053/gast.2002.32997
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129(3):837–845. doi: 10.1053/j.gastro.2005.06.020
   PubMed Web of Science ®Google Scholar
• Cohen SA, Wu C, Yu M, et al. Evaluation of CpG island methylator phenotype as a biomarker in colorectal cancer treated with adjuvant oxaliplatin. Clin Colorectal Cancer. 2016;15(2):164–169. doi: 10.1016/j.clcc.2015.10.005
   PubMed Web of Science ®Google Scholar
• Yu J, Liang QY, Wang J, et al. Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene. 2013;32(3):307–317. doi: 10.1038/onc.2012.54
   PubMed Web of Science ®Google Scholar
• Vedeld HM, Andresen K, Eilertsen IA, et al. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers. Int J Cancer. 2015;136(4):844–853. doi: 10.1002/ijc.29039
   PubMed Web of Science ®Google Scholar
• Wang Y, He T, Herman JG, et al. Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth. Clin Epigenetics. 2017;9(1):115. doi: 10.1186/s13148-017-0417-4
   PubMedGoogle Scholar
• Vedeld HM, Nesbakken A, Lothe RA, et al. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin Epigenetics. 2018;10(70). doi: 10.1186/s13148-018-0503-2
   PubMedGoogle Scholar
• Jiang S, Linghu E, Zhan Q, et al. Methylation of ZNF331 promotes cell invasion and migration in human esophageal cancer. Curr Protein Pept Sci. 2015;16(4):322–328. doi: 10.2174/138920371604150429155255
   PubMed Web of Science ®Google Scholar
• Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456–3461. doi: 10.1200/JCO.2007.11.2144
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005;33(21):6823–6836. doi: 10.1093/nar/gki987
   PubMed Web of Science ®Google Scholar
• Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006;8(2):209–217. doi: 10.2353/jmoldx.2006.050135
   PubMed Web of Science ®Google Scholar
• Ogino S, Meyerhardt JA, Cancer and Leukemia Group B, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15(23):7322–7329. doi: 10.1158/1078-0432.CCR-09-1570
   PubMed Web of Science ®Google Scholar
• Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18(3):890–900. doi: 10.1158/1078-0432.CCR-11-2246
   PubMed Web of Science ®Google Scholar
• Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6):847–854. doi: 10.1136/gutjnl-2011-300865
   PubMed Web of Science ®Google Scholar
• Drmanac S, Kita D, Labat I, et al. Accurate sequencing by hybridization for DNA diagnostics and individual genomics. Nat Biotechnol. 1998;16(1):54–58. doi: 10.1038/nbt0198-54
   PubMed Web of Science ®Google Scholar
• Warren RS, Atreya CE, Niedzwiecki D, et al. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013;19(20):5777–5787. doi: 10.1158/1078-0432.CCR-13-0351
   PubMed Web of Science ®Google Scholar
• Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248–5257.
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol. 2009;27(11):1814–1821. doi: 10.1200/JCO.2008.18.2071
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of Heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer – A study of CALGB 9581 and 89803. J Clin Oncol. 2011;29(23):3153–3162. doi: 10.1200/JCO.2010.33.0092
   PubMed Web of Science ®Google Scholar
• Shiovitz S, Bertagnolli MM, Alliance for Clinical Trials in Oncology, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014;147(3):637–645. doi: 10.1053/j.gastro.2014.05.009
   PubMed Web of Science ®Google Scholar
• Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18(1):50–60. doi: 10.1214/aoms/1177730491
   Google Scholar
• Cochran WG. The χ2 Test of Goodness of Fit. Ann Math Stat. 1952;23(3):315–345. doi: 10.1214/aoms/1177729380
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481. doi: 10.2307/2281868
   Web of Science ®Google Scholar
• Cox DR. Regression models and Life-Tables. J R Stat Soc Series B: Stat Methodol. 1972;34(2):187–220. doi: 10.1111/j.2517-6161.1972.tb00899.x
   Web of Science ®Google Scholar
• van Engeland M, Derks S, Smits KM, et al. Colorectal cancer epigenetics: complex simplicity. J Clin Oncol. 2011;29(10):1382–1391. doi: 10.1200/JCO.2010.28.2319
   PubMed Web of Science ®Google Scholar
• Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12(6):621–628. doi: 10.1586/erm.12.46
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome – biological and translational implications. Nat Rev Cancer. 2011;11(10):726–734. doi: 10.1038/nrc3130
   PubMed Web of Science ®Google Scholar
• Ebert MP, Tänzer M, Balluff B, et al. TFAP2E–DKK4 and chemoresistance in colorectal cancer. N Engl J Med. 2012;366(1):44–53. doi: 10.1056/NEJMoa1009473
   PubMed Web of Science ®Google Scholar
• Moutinho C, Martinez-Cardús A, Santos C, et al. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. J Natl Cancer Inst. 2014;106(1):djt322. doi: 10.1093/jnci/djt322
   PubMedGoogle Scholar